Research programme: allergy/asthma therapy - Santaris/Rigshospitalet
Alternative Names: Allergy/asthma therapy research programme - Santaris/RigshospitaletLatest Information Update: 21 Aug 2009
Price :
$50 *
At a glance
- Originator Rigshospitalet; Santaris Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Hypersensitivity
Most Recent Events
- 21 Aug 2009 Discontinued - Preclinical for Allergy in Denmark (unspecified route)
- 21 Aug 2009 Discontinued - Preclinical for Asthma in Denmark (unspecified route)
- 01 Jul 2003 Pantheco has merged with Cureon to form Santaris Pharma